<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00586547</url>
  </required_header>
  <id_info>
    <org_study_id>H-9033</org_study_id>
    <nct_id>NCT00586547</nct_id>
    <nct_alias>NCT00622297</nct_alias>
  </id_info>
  <brief_title>Evaluating the Use of RFT5-dgA to Deplete Alloreactive Cells Prior to Haploidentical Stem Cell Transplantation</brief_title>
  <official_title>A Phase I Trial Evaluating The Use of RFT5-dgA to Deplete Alloreactive Cells PriorTo Haploidentical Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Texas, Southwestern Medical Center at Dallas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine the number of donor lymphocytes that can be given to&#xD;
      recipients of haploidentical stem cell transplants after depletion of recipient-reactive T&#xD;
      lymphocytes by ex-vivo treatment with a fixed dose of RFT5-dgA immunotoxin, and will result&#xD;
      in a rate of Grade III/IV GVHD of &lt; / = 25%, to analyze immune reconstitution in these&#xD;
      patients, and to measure their overall and disease free survival, at 100 days and at 1 year.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive cytosine arabinoside (3g/m^2) IV every 12 hours for 6 doses starting at&#xD;
      1400 hours on day -8. Cyclophosphamide (45mg/kg) will be given on Day -7 and Day -6. MESNA&#xD;
      (45mg/kg, divided into 5 doses) will be administered 15 minutes prior to each dose of&#xD;
      cyclophosphamide and 3, 6, 9 and12 hours after each dose of cyclophosphamide. Campath 1H IV&#xD;
      will be given on Days -3, -2 and -1. TBI, total dose 14.0 Gy will be delivered in 8 fractions&#xD;
      of 1.75 Gy in two fractions per day beginning Day -4. The dose rate will be 10cGy/min.&#xD;
&#xD;
      Approximately thirty days following transplantation (day +30), the cryopreserved T cells will&#xD;
      be thawed and infused through a catheter line with normal saline.&#xD;
&#xD;
      This study will begin with a dose of T cells known not to cause GvHD even in haploidentical&#xD;
      recipients, even when the T cells administered have not first been allodepleted. A subset of&#xD;
      patients who achieved engraftment will be included in the dose escalation study of&#xD;
      allodepleted T-cells treated with RFT5-dgA. A continual reassessment method based on a&#xD;
      logistic dose-response curve with cohorts of size 2 will be employed to determine the MTD.&#xD;
      Cohorts of size 2 will be accrued beginning at dose level 1 and the dose-response curve is&#xD;
      estimated after toxicity outcome is observed to determine the recommended dose level for the&#xD;
      next patient cohort. Each and every patient will receive up to five additional injections of&#xD;
      T cells at the same dose, at monthly intervals, provided there is no evidence of grade 2 or&#xD;
      higher GVHD, until total T cell numbers are &gt; 1000/ul&#xD;
&#xD;
      Patients will be entered starting at level 1, according to the following doses:&#xD;
&#xD;
      Dose level -1 (1 x 10^3 T cells/Kg); Dose level 1 (1 x 10^4 T cells/Kg); Dose level 2 (1 x&#xD;
      10^5 T cells/Kg); Dose level 3 (1 x 10^6 T cells/Kg); Dose level 4 (5 x 10^6 T cells/Kg).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2000</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determining the number of donor lymphocytes given to recipients of haploidentical stem cell transplants after depletion of recipient-reactive T lymphocytes by ex-vivo treatment with a fixed dose of RFT5-dgA immunotoxin.</measure>
    <time_frame>100</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure their overall and disease free survival.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Leukemia</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After patients have completed preparation to receive cells, they will be treated at one of five dose levels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>T-Cell Infusion Dose Level -1</intervention_name>
    <description>(1 x 10^3 T cells/Kg)</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>T-Cell Infusion Dose Level 1</intervention_name>
    <description>(1 x 10^4 T cells/Kg)</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>T-Cell Infusion Dose Level 2</intervention_name>
    <description>(1 x 10^5 T cells/Kg)</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>T-Cell Infusion Dose Level 3</intervention_name>
    <description>(1 x 10^6 T cells/Kg)</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>T-Cell Infusion- Dose Level 4</intervention_name>
    <description>(5 x 10^6 T cells/Kg)</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ALL or high grade NHL that is Stage III or IV and has relapsed or is considered to be&#xD;
             primary refractory disease.&#xD;
&#xD;
          -  Myelodysplastic syndrome.&#xD;
&#xD;
          -  AML after first relapse or with primary refractory disease.&#xD;
&#xD;
          -  CML hemophagocytic lymphohistiocytosis (HLH)&#xD;
&#xD;
          -  Familial hemophagocytic lymphohistiocytosis (FLH)&#xD;
&#xD;
          -  Viral-associated hemophagocytic syndrome (VAHS)&#xD;
&#xD;
          -  X-linked lymphoproliferative disease (XLP)&#xD;
&#xD;
          -  Patients with Severe chronic active Epstein Barr virus infection (SCAEBV) with&#xD;
             predilection for T- or NK-cell malignancy&#xD;
&#xD;
          -  Lack of suitable conventional donor (i.e. 5/6 or 6/6 related or 5/6 or 6/6 unrelated&#xD;
             donor) or presence of a rapidly progressive disease not permitting time to identify an&#xD;
             unrelated donor.&#xD;
&#xD;
          -  Donor cells should be collected and frozen before conditioning starts.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a life expectancy (&lt; or = to 6 weeks) limited by diseases other than&#xD;
             leukemia.&#xD;
&#xD;
          -  Patients with symptomatic cardiac disease, or evidence of significant cardiac disease&#xD;
             by echocardiogram (i.e. shortening fraction &lt; 25%)&#xD;
&#xD;
          -  Patients with severe renal disease (i.e. creatinine clearance less than 40cc/1.73m2)&#xD;
&#xD;
          -  Patients with pre-existing severe restrictive pulmonary disease (FVC less than 40% of&#xD;
             predicted)&#xD;
&#xD;
          -  Patients with severe hepatic disease (direct bilirubin greater than 3ug/dl or SGPT&#xD;
             greater than 500ug/dl)&#xD;
&#xD;
          -  Patients with severe personality disorder or mental illness that would preclude&#xD;
             compliance with the study&#xD;
&#xD;
          -  Patients with a severe infection that on evaluation by the Principal Investigator&#xD;
             precluded ablative chemotherapy or successful transplantation&#xD;
&#xD;
          -  Patients with documented HIV positivity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malcolm Brenner, MB, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2008</study_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Malcolm Brenner</investigator_full_name>
    <investigator_title>Dist Serv Prof, Center for Gene Therapy</investigator_title>
  </responsible_party>
  <keyword>Haploidentical</keyword>
  <keyword>Stem Cell Transplant</keyword>
  <keyword>Graft-Versus-Host disease</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

